ImageneBio reports Q4 2025 net loss $6.9M; cash $135.3M; Phase 2b ADAPTIVE on track for 2027

ImageneBio, Inc.

Cash, equivalents and marketable securities: $135.3M at Dec 31, 2025 vs $12.1M at Dec 31, 2024, after merger and $75M private placement.
Net loss Q4 2025: $6.9M vs $4.8M Q4 2024, driven by post-merger operating costs and transaction expenses.
Phase 2b ADAPTIVE trial (IMG-007 in atopic dermatitis) enrolling on schedule; blinded safety review found no pyrexia/chills/ulcers/malignancies.
Appointed Dr. Ben Porter-Brown as CMO in Feb 2026; also added CEO, CSO, CTO, and an independent director during 2025.
Submitted protocol amendment to expand dosing regimens, evaluate loading doses, and test patient-friendly intervals in ADAPTIVE.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-099422
form_type: 8-K
ticker: IMA
cik: 0001835579
company_name: ImageneBio, Inc.
filed_at: 2026-03-10T23:59:59+00:00
discovered_at: 2026-05-14T18:02:36.451617+00:00
generated_at: 2026-05-15T16:57:18.339362+00:00
sec_items: ["2.02", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.65
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-099422
json_url: https://secwatch.observer/filing/0001193125-26-099422.json
markdown_url: https://secwatch.observer/filing/0001193125-26-099422.md
text_url: https://secwatch.observer/filing/0001193125-26-099422.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1835579/000119312526099422/0001193125-26-099422-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1835579/000119312526099422/d130344d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-099422

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.